Literature DB >> 28012103

Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease.

Mimi C Tan1,2, Hashem B El-Serag3,4, Jason K Hou3,4.   

Abstract

BACKGROUND: Identifying patient-level and disease-specific predictors of healthcare utilization in inflammatory bowel disease (IBD) may allow targeted interventions to reduce costs and improve outcomes. AIM: To identify demographic and clinical predictors of healthcare utilization among veterans with IBD.
METHODS: We conducted a single-center cross-sectional study of veterans with IBD from 1998 to 2010. Demographics and disease characteristics were abstracted by manual chart review. Annual number of IBD-related visits was estimated by dividing total number of IBD-related inpatient and outpatient encounters by duration of IBD care. Associations between predictors of utilization were determined using stepwise multivariable linear regression.
RESULTS: Overall, 676 patients (56% ulcerative colitis (UC), 42% Crohn's disease (CD), and 2% IBD unclassified (IBDU)) had mean 3.08 IBD-related encounters annually. CD patients had 3.59 encounters compared to 2.73 in UC (p < 0.01). In the multivariable model, Hispanics had less visits compared to Caucasians and African-Americans (2.09 vs. 3.09 vs. 3.42), current smokers had more visits than never smokers (3.54 vs. 2.43, p = 0.05), and first IBD visit at age <40 had more visits than age >65 (3.84 vs. 1.75, p = 0.04). UC pancolitis was associated with more visits than proctitis (3.47 vs. 2.15, p = 0.04). CD penetrating phenotype was associated with more encounters than inflammatory type (4.68 vs. 4.15, p = 0.04).
CONCLUSIONS: We found that current tobacco use, age <40 at first IBD visit, UC pancolitis, and CD fistuilizing phenotype in addition to Caucasian and African-American race were independent predictors of increased healthcare utilization. Interventions should be targeted at these groups to decrease healthcare utilization and costs.

Entities:  

Keywords:  Crohn’s disease; Health service utilization; Healthcare utilization; Inflammatory bowel disease; Outcomes research; Ulcerative colitis

Mesh:

Year:  2016        PMID: 28012103     DOI: 10.1007/s10620-016-4414-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

2.  Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease.

Authors:  Harminder Singh; Zoann Nugent; Laura E Targownik; Wael El-Matary; Marni Brownell; Charles N Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-28       Impact factor: 11.382

3.  [Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology].

Authors:  Michel Dapoigny; François Dyard; Jean-Charles Grimaud; Philippe Guyot; Eric van Ganse
Journal:  Gastroenterol Clin Biol       Date:  2003-03

4.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

5.  Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians.

Authors:  Jason Hou; Hashem El-Serag; Joseph Sellin; Selvi Thirumurthi
Journal:  Dig Dis Sci       Date:  2011-03-11       Impact factor: 3.199

6.  Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Authors:  Uwe Siebert; Johannes Wurm; Raffaella Matteucci Gothe; Marjan Arvandi; Stephan R Vavricka; Roland von Känel; Stefan Begré; Michael C Sulz; Christa Meyenberger; Markus Sagmeister
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

7.  Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort.

Authors:  Peter L Lakatos; Zsuzsanna Vegh; Barbara D Lovasz; Gyula David; Tunde Pandur; Zsuzsanna Erdelyi; Istvan Szita; Gabor Mester; Mihaly Balogh; Istvan Szipocs; Csaba Molnar; Erzsebet Komaromi; Petra A Golovics; Michael Mandel; Agnes Horvath; Miklos Szathmari; Lajos S Kiss; Laszlo Lakatos
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

8.  Depressive mood and disease activity in inflammatory bowel disease.

Authors:  Sima Besharat; Taghi Amiriani; Gholamreza Roshandel; Mahsa Besharat; Shahryar Semnani; Mohammadzaman Kamkar
Journal:  Arab J Gastroenterol       Date:  2012-09-03       Impact factor: 2.076

9.  Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study.

Authors:  H H Thein; Y Qiao; S K Young; W Zarin; E M Yoshida; C de Oliveira; C C Earle
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

10.  Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study.

Authors:  Michael C Sulz; Uwe Siebert; Marjan Arvandi; Raffaella M Gothe; Johannes Wurm; Roland von Känel; Stephan R Vavricka; Christa Meyenberger; Markus Sagmeister
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-07       Impact factor: 2.566

View more
  4 in total

1.  Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease.

Authors:  Kaleb Bogale; Parth Maheshwari; Mitchell Kang; Venkata Subhash Gorrepati; Shannon Dalessio; Vonn Walter; August Stuart; Walter Koltun; Nana Bernasko; Andrew Tinsley; Emmanuelle D Williams; Kofi Clarke; Matthew D Coates
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

2.  Elderly-Onset and Adult-Onset Ulcerative Colitis Are More Similar than Previously Reported in a Nationwide Cohort.

Authors:  Vinayak Kumar; Yash Shah; Dhruvan Patel; Nabeel Khan
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

3.  Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis.

Authors:  Murtaza M Tambuwala; Mohammed N Khan; Paul Thompson; Paul A McCarron
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

4.  Predictors of High Health Care Utilization in Patients With Inflammatory Bowel Disease Within 1 Year of Establishing Specialist Care.

Authors:  Kenechukwu Chudy-Onwugaje; Alexander P Mamunes; David A Schwartz; Sara Horst; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 5.325

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.